ClinicalTrials.gg
CompletedNCT00796718Updated Aug 25, 2016Results posted

A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer

A Phase 2 interventional study of Standard radiotherapy and Capecitabine [Xeloda] in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 2 sites in Slovakia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-08-25.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 179 studies testing capecitabine in Colorectal Neoplasms — 24 open to participants now, 32 under way, 7 of them phase 3. Capecitabine · Colorectal Neoplasms.

Enrollment
82nd of 173
62 · median 55
Started
2008
with 8 others
Phase 2
100 of 179
16 open now
Registered
78th of 179
by date
Lead sponsor
16 of 179
Hoffmann-La Roche

Among the 179 studies testing capecitabine in Colorectal Neoplasms, this one is the 82nd largest by enrollment of the 173 interventional ones that give a count, is one of 9 that started in 2008, is one of 100 in phase 2, and was the 78th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

24 of the 179 studies testing capecitabine in Colorectal Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 24 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies testing capecitabine in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This single arm study will assess the efficacy and safety of treatment with Xeloda plus standard pelvic radiotherapy in participants with locally advanced rectal cancer. Eligible participants will receive Xeloda 825mg/m\^2 orally twice daily plus standard radiotherapy for 5 weeks, followed by surgery within 6 weeks after completion of treatment. The anticipated time on study treatment is \< 3 months, and the target sample size is \< 100 individuals.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, 18-80 years of age;
  • rectal cancer;
  • planned surgery, and likely to benefit from pre-operative combined chemo-radiotherapy;
  • (ECOG) performance status 0-2

Exclusion criteria

Exclusion Criteria:

  • previous radiotherapy or chemotherapy for colorectal cancer;
  • cardiovascular disease;
  • significant gastric or small intestine disease;
  • serious uncontrolled active infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Capecitabine

    Capecitabine orally twice daily plus standard radiotherapy for 5 weeks, followed by surgery within 6 weeks after completion of treatment.

    Radiation: Standard radiotherapy · Drug: Capecitabine [Xeloda]

Interventions

  • RadiationStandard radiotherapy

    Administered as prescribed according to normal clinical practice.

  • 825 milligrams per meter square (mg/m\^2) orally twice daily for 5 weeks.

    Also known as: Xeloda®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Pathological Complete Response

    Pathological complete response was defined as the absence of viable tumor cells in the tumor specimen, including regional lymph nodes determined with standard histological procedures.

    Time frame: Up to 11 weeks (assessed at the time of post-treatment surgery)

Secondary outcomes

  1. Percentage of Participants With Response to Treatment Assessed 4-6 Weeks After the Completion of Radiochemotherapy (Complete Response, Partial Remission or No Response to the Treatment)

    Complete response was defined as the disappearance of all target and non-target lesions. Partial remission was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of target lesions, taking as reference the baseline SLD, or the persistence of 1 or more non-target lesions. No response to treatment was defined as neither sufficient shrinkage to qualify for partial remission nor sufficient increase to qualify for progressive disease, compared to the baseline SLD.

    Time frame: Up to 11 weeks (assessed 4-6 weeks after the completion of radiochemotherapy)

  2. Percentage of Participants With Response to the Treatment Assessed 1 Month After Surgery (Complete Response, Partial Remission or No Response to the Treatment)

    Complete response was defined as the disappearance of all target and non-target lesions. Partial remission was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of target lesions, taking as reference the baseline SLD, or the persistence of 1 or more non-target lesions. No response to treatment was defined as neither sufficient shrinkage to qualify for partial remission nor sufficient increase to qualify for progressive disease, compared to the baseline SLD.

    Time frame: Up to 15 weeks (assessed 1 month after surgery)

  3. Percentage of Participants With Adverse Events

    An adverse event was defined as any untoward medical occurrence in a participant administered the investigational product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 15 weeks

07

Results

Posted Aug 25, 2016

Participant flow

Participant flow — Overall Study
MilestoneCapecitabine
Started62
Completed53
Not completed9
Withdrew: Adverse event2
Withdrew: Exclusion criteria1
Withdrew: Lost to follow-up5
Withdrew: Withdrawal by informed consent1

Outcome measures

PrimaryPercentage of Participants With Pathological Complete Response

Pathological complete response was defined as the absence of viable tumor cells in the tumor specimen, including regional lymph nodes determined with standard histological procedures.

Time frame:
Up to 11 weeks (assessed at the time of post-treatment surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With Pathological Complete Response
percentage of participantsCapecitabine
Percentage of Participants With Pathological Complete Response16
SecondaryPercentage of Participants With Response to Treatment Assessed 4-6 Weeks After the Completion of Radiochemotherapy (Complete Response, Partial Remission or No Response to the Treatment)

Complete response was defined as the disappearance of all target and non-target lesions. Partial remission was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of target lesions, taking as reference the baseline SLD, or the persistence of 1 or more non-target lesions. No response to treatment was defined as neither sufficient shrinkage to qualify for partial remission nor sufficient increase to qualify for progressive disease, compared to the baseline SLD.

Time frame:
Up to 11 weeks (assessed 4-6 weeks after the completion of radiochemotherapy)
Reported as:
Number · percentage of participants
Percentage of Participants With Response to Treatment Assessed 4-6 Weeks After the Completion of Radiochemotherapy (Complete Response, Partial Remission or No Response to the Treatment)
percentage of participantsCapecitabine
Complete Response2
Partial Remission12.2
No Response77.6
SecondaryPercentage of Participants With Response to the Treatment Assessed 1 Month After Surgery (Complete Response, Partial Remission or No Response to the Treatment)

Complete response was defined as the disappearance of all target and non-target lesions. Partial remission was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of target lesions, taking as reference the baseline SLD, or the persistence of 1 or more non-target lesions. No response to treatment was defined as neither sufficient shrinkage to qualify for partial remission nor sufficient increase to qualify for progressive disease, compared to the baseline SLD.

Time frame:
Up to 15 weeks (assessed 1 month after surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With Response to the Treatment Assessed 1 Month After Surgery (Complete Response, Partial Remission or No Response to the Treatment)
percentage of participantsCapecitabine
Complete Response56
Partial Remission10
No Response14
SecondaryPercentage of Participants With Adverse Events

An adverse event was defined as any untoward medical occurrence in a participant administered the investigational product which does not necessarily have a causal relationship with this treatment.

Time frame:
Up to 15 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events
percentage of participantsCapecitabine
Percentage of Participants With Adverse Events91.9

Adverse events

Collected over Up to 15 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capecitabine—4/62 (6.5%)49/62 (79%)
Most frequent serious events
Most frequent serious events
EventCapecitabine
DiarrheaGastrointestinal disorders2/62
Ventricular fibrillationCardiac disorders1/62
Hemorrhoidal inflammationGastrointestinal disorders1/62
IleusGastrointestinal disorders1/62
SepsisInfections and infestations1/62
Most frequent other events
Showing 10 of 14
Most frequent other events
EventCapecitabine
DiarrheaGastrointestinal disorders21/62
Dermatitis radiationInjury, poisoning and procedural complications20/62
Rectal painGastrointestinal disorders12/62
LeukopeniaBlood and lymphatic system disorders8/62
Abdominal painGastrointestinal disorders8/62
NauseaGastrointestinal disorders7/62
FatigueGeneral disorders6/62
NeutropeniaBlood and lymphatic system disorders5/62
AnemiaBlood and lymphatic system disorders4/62
Upper respiratory infectionInfections and infestations4/62

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Capecitabine
Mean59.0 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Capecitabine
Female22
Male40
08

Study locations

2 sites
  • Banska Bystrica, 975 17, Slovakia
  • Bratislava, 833 10, Slovakia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 6 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2008
First posted
Nov 24, 2008
Start
Oct 2008
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Results first posted
Aug 25, 2016
Last update
Aug 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00796718
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 24, 2008
Start date
Oct 2008
Primary completion
Aug 2010
Completion
Aug 2010
Results posted
Aug 25, 2016
Last update
Aug 25, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capecitabine

Start the discussion